Comparison 5. Fondaparinux versus LMWH.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 total VTE	11	9339	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.42, 0.73]
2 symptomatic VTE	9	12240	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.65, 1.63]
3 total DVT	10	9356	Risk Ratio (M‐H, Random, 95% CI)	0.54 [0.40, 0.71]
4 proximal DVT	9	8361	Risk Ratio (M‐H, Random, 95% CI)	0.58 [0.33, 1.02]
5 total PE	10	12350	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.65, 2.34]
6 fatal PE	9	11107	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.25, 2.05]
7 non‐fatal PE	9	11107	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [0.63, 3.11]
8 major bleeding	11	12501	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [1.09, 1.75]
9 fatal bleeding	6	10293	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.14, 3.62]
10 MI	6	10720	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.69, 2.37]
11 all causes of death	11	12400	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.63, 1.22]
12 death associated with VTE or bleeding	5	4774	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.38, 2.07]
13 other serious adverse effects	10	12465	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.94, 1.19]